Sanofi (NASDAQ:SNY) Lowered to Buy at StockNews.com

StockNews.com downgraded shares of Sanofi (NASDAQ:SNY) from a strong-buy rating to a buy rating in a report released on Monday morning.

Separately, Argus lifted their price objective on Sanofi from $55.00 to $60.00 and gave the company a buy rating in a research note on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $57.50.

Sanofi Trading Down 0.1 %

Shares of NASDAQ SNY opened at $53.53 on Monday. Sanofi has a twelve month low of $42.63 and a twelve month high of $55.72. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a fifty day simple moving average of $50.10 and a 200-day simple moving average of $48.78. The stock has a market capitalization of $135.58 billion, a PE ratio of 26.90, a PEG ratio of 1.52 and a beta of 0.59.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The business had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. During the same period in the previous year, the firm posted $0.95 earnings per share. The company’s revenue was up 7.8% on a year-over-year basis. On average, equities analysts forecast that Sanofi will post 4.18 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. TCTC Holdings LLC grew its stake in Sanofi by 28.0% during the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock worth $47,000 after purchasing an additional 210 shares in the last quarter. Daiwa Securities Group Inc. grew its stake in Sanofi by 3.4% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock worth $325,000 after purchasing an additional 216 shares in the last quarter. HB Wealth Management LLC grew its stake in Sanofi by 3.7% during the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock worth $299,000 after purchasing an additional 221 shares in the last quarter. Wynn Capital LLC lifted its holdings in Sanofi by 4.5% during the 1st quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock worth $256,000 after buying an additional 226 shares during the last quarter. Finally, Insigneo Advisory Services LLC lifted its holdings in Sanofi by 3.3% during the 2nd quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company’s stock worth $371,000 after buying an additional 228 shares during the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.